TNFRSF9 and renal cell adenocarcinoma: These data suggest that a subpopulation may potentially exert a critical antitumor effect through combination immunotherapy with anti-PD1-blocking agents and CD137 agonists, opening up possible new therapeutic strategies in the management of advanced RCC patients.